CSL Limited is one of the world’s leading companies specializing in blood plasma therapies, nephrology, and vaccines. The ...

Csl Ltd ( ($CSLLY) ) has released its Q2 earnings. Here is a breakdown of the information Csl Ltd presented to its investors.

CSL delivered a messy result. Although they did say they are on track to achieve FY guidance, gross margins and 1H adjusted ...

CEO Paul McKenzie announced a reaffirmation of guidance for fiscal 2025, targeting NPATA growth of 10% to 13%. He highlighted strong results from CSL Behring and growth in CSL Vifor, while ...

In a report released today, Steven Wheen from Jarden maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of A$314.37.

CSL Limited (OTC:CSLLY) and uniQure Inc (NASDAQ:QURE) announced the four-year results from the pivotal HOPE-B study ...

A weak vaccine result dragged on CSL's H1 result but analysts focus on an improving plasma product margin and solid growth ...

The ASX-listed pharmaceutical giant has shrugged off a sluggish period and says it expects profits to rise by more than 10 ...

In a report released yesterday, David Stanton from Jefferies maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of ...

Australian biopharmaceutical company CSL posted higher first-half profits as growth in its main blood-plasma business helped offset weaker flu vaccine sales, which were hit by "significantly" low ...

“CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in ...

CSL Seqirus, the vaccination segment, was affected by low influenza vaccination rates in the US, dragging down overall ...